TARGET based m6A methylation-related genes predict prognosis relapsed B-cell acute lymphoblastic leukemia

IF 2 3区医学 Q2 PEDIATRICS

BMC Pediatrics Pub Date : 2024-09-10 DOI:10.1186/s12887-024-05053-x

Kun-yin Qiu, Xiong-yu Liao, Jian-pei Fang, Dun-hua Zhou

{"title":"TARGET based m6A methylation-related genes predict prognosis relapsed B-cell acute lymphoblastic leukemia","authors":"Kun-yin Qiu, Xiong-yu Liao, Jian-pei Fang, Dun-hua Zhou","doi":"10.1186/s12887-024-05053-x","DOIUrl":null,"url":null,"abstract":"The current study aims to investigate the significance of N6-methyladenosine (m6A) methylationrelated genes in the clinical prognosis of childhood relapsed B-cell acute lymphoblastic leukemia (B-ALLL) patient. Transcriptome data and corresponding clinical data on m6A methylation-related genes (including 20 genes) were obtained from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) database. The bone marrow (BM) samples of 134 newly diagnosed (naive) and 116 relapsed B-ALL from TARGET were enrolled in the current study. Three genes (FTO, HNRNPC, RBM15B) showed significant up-regulation in relapsed B-ALL compared with that in naive B-ALL.The three genes had a significantly worse survival (P < 0.05). The LASSO Cox regression model was used to select the most predictive genes as prognostic indicators, and YTHDC1 and FTO were identified as prognostic factors for relapsed B-ALL. Finally, the results of multivariate regression analysis showed that the risk score of m6A methylation-related genes was an independent prognostic factor in relapsed B-ALL (P < 0.05). We found that the expression levels of m6A methylation-related genes were different in naive and relapsed patients with B-ALL and correlated with survival and prognosis.This implies that m6A methylation-related genes may be promising prognostic indicators or therapeutic targets for relapsed B-ALL.","PeriodicalId":9144,"journal":{"name":"BMC Pediatrics","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12887-024-05053-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

The current study aims to investigate the significance of N6-methyladenosine (m6A) methylationrelated genes in the clinical prognosis of childhood relapsed B-cell acute lymphoblastic leukemia (B-ALLL) patient. Transcriptome data and corresponding clinical data on m6A methylation-related genes (including 20 genes) were obtained from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) database. The bone marrow (BM) samples of 134 newly diagnosed (naive) and 116 relapsed B-ALL from TARGET were enrolled in the current study. Three genes (FTO, HNRNPC, RBM15B) showed significant up-regulation in relapsed B-ALL compared with that in naive B-ALL.The three genes had a significantly worse survival (P < 0.05). The LASSO Cox regression model was used to select the most predictive genes as prognostic indicators, and YTHDC1 and FTO were identified as prognostic factors for relapsed B-ALL. Finally, the results of multivariate regression analysis showed that the risk score of m6A methylation-related genes was an independent prognostic factor in relapsed B-ALL (P < 0.05). We found that the expression levels of m6A methylation-related genes were different in naive and relapsed patients with B-ALL and correlated with survival and prognosis.This implies that m6A methylation-related genes may be promising prognostic indicators or therapeutic targets for relapsed B-ALL.

查看原文本刊更多论文

基于 TARGET 的 m6A 甲基化相关基因可预测复发 B 细胞急性淋巴细胞白血病的预后

本研究旨在探讨N6-甲基腺苷（m6A）甲基化相关基因在儿童复发性B细胞急性淋巴细胞白血病（B-ALLL）患者临床预后中的意义。m6A甲基化相关基因（包括20个基因）的转录组数据和相应的临床数据来自治疗性研究产生有效治疗（TARGET）数据库。本研究从 TARGET 数据库中选取了 134 例新诊断（幼稚型）和 116 例复发 B-ALL 的骨髓（BM）样本。与新诊断的B-ALL相比，复发B-ALL中有三个基因（FTO、HNRNPC和RBM15B）出现显著上调。利用LASSO Cox回归模型选择最具预测性的基因作为预后指标，YTHDC1和FTO被确定为复发B-ALL的预后因素。最后，多变量回归分析结果显示，m6A甲基化相关基因的风险评分是复发B-ALL的独立预后因素（P＜0.05）。我们发现，m6A甲基化相关基因的表达水平在新发和复发的B-ALL患者中存在差异，并与患者的生存和预后相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Pediatrics PEDIATRICS-

CiteScore

3.70

自引率

4.20%

发文量

683

审稿时长

3-8 weeks

期刊介绍： BMC Pediatrics is an open access journal publishing peer-reviewed research articles in all aspects of health care in neonates, children and adolescents, as well as related molecular genetics, pathophysiology, and epidemiology.